BCYC (BCYC) Stock Price & Analysis
BCYC (BCYC) rose 1.42% to USD 4.3 as of September 8, 2026 at 06:57 UTC, according to Nexqual real-time market data.
BCYC last closed at USD 4.3; the session ranged USD 4.2–4.3 on volume of 157,468 shares. Market capitalization is —, with a 52-week range of USD 3.75–9.16 (NMS). Source: Nexqual, September 8, 2026 at 06:57 UTC.
Key Statistics (as of September 8, 2026 at 06:57 UTC)
| Price | USD 4.3 |
|---|---|
| Change | ▲ 1.42% (up) |
| Previous Close | USD 4.3 |
| Open | USD 4.3 |
| Day Range | USD 4.2 – 4.3 |
| 52-Week Range | USD 3.75 – 9.16 |
| Volume | 157,468 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (BCYC)
Nexqual's technical model rates BCYC "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:57 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.84 (neutral) |
| vs SMA50 | Above (USD 4.15) |
| MACD | 0.04 (positive) |
From BCYC's Latest SEC 10-K Filing (filed 2026-03-17)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | USD 39.86 | ▼ 0.77% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 84.95 | ▲ 0% |
| ARVN | Arvinas, Inc. | USD 9.39 | ▼ 2.09% |
| STRO | Sutro Biopharma, Inc. | USD 20.07 | ▼ 1.95% |
| KROS | Keros Therapeutics, Inc. | USD 11.32 | ▲ 0.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:57 UTC. This page is informational and not investment advice.